Introduction
Empyema thoracis, which is the presence of pus in the pleural space, [1] [2] [3] remains a problem in developing countries. 4 Its course is often prolonged, and it frequently requires surgical drainage. Human immunodeficiency virus (HIV) infection is a risk factor for empyema, 1 and complicates pneumonia more frequently in HIV-infected patients. 5 Reported risk factors for the development of empyema include serum albumin < 30 g/ dl, intravenous drug use, ethanol abuse, a younger age, male gender, and current smoking status. 6 In our experience, the majority of patients with empyema are HIV infected, and present with late stages of empyema. Despite the expected low success rates of closed-tube thoracostomy in the treatment of late empyema, 7 it remains as first-line therapy at our hospital, as cardiothoracic services are limited and many patients are critically ill and unable to tolerate aggressive surgical procedures.
There is an impression that HIV-infected patients experience worse clinical outcomes. Limited literature exists to support this. Some reports claim that patients with CD4 counts < 200 cells/mm 3 have higher complication rates, and a poorer prognosis. 5 This study compares microbiological aetiology and outcomes, including length of stay, whether surgical intervention was offered and local complications of tube thoracostomy, in patients with empyema according to HIV status. A secondary objective was to compare aetiology and outcomes in patients with HIV infection, stratified according to their CD4 cell count (≥ 200 cells/mm 3 or < 200 cells/mm 3 ) and antiretroviral (ARV) usage.
Method
Chris Hani Baragwanath Hospital (CHBH) is a large academic hospital in Soweto, Johannesburg, with 847 medical beds. It is the only in-patient facility for the greater Soweto area, and serves as a referral centre for southern Gauteng and the North West province. The CHBH respiratory unit database, from January 2006 to December 2009, was reviewed. An Excel ® (Microsoft Corporation, Bellevue, Washington) database was compiled from discharge summaries, and case notes of patients referred to the respiratory unit. Permission to use the database was obtained from the database manager, and permission to conduct this review was obtained from the Human Research Ethics Committee of the University of the Witwatersrand.
Patients meeting at least one of the following established criteria of empyema were included:
• Aspiration of pus from the pleural space • Pleural fluid pH < 7.2, or pleural fluid glucose < 3.4 mmol/l • Positive microbial stain and/or culture. Complications were defined as:
• Wound sepsis at the tube thoracostomy site • Secondary infection of the pleural space.
Statistical analysis was performed using STATA ® 10 software (StataCorp LP, College Station, Texas). Univariate analyses were performed in each of the groups, against known risk factors for empyema: age, smoking, ethanol abuse and male sex. Associations between categorical variables were tested using Fisher's exact test, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Continuous variables with parametric distributions were tested with the Student's t-test, and those with nonparametric distributions with the Wilcoxon rank-sum test. Where significant risk factors were identified between groups, they were analysed using multivariate regression analyses. Significance was considered as a p-value of < 0.05.
Results
Of the 250 patient records reviewed, 78 patients were excluded (see Figure 1) . The 29 patients excluded for chronic or unresolved empyema were patients who had been previously admitted for primary empyema prior to the date that this study commenced, and had returned with complications during the study period. It was felt that inclusion of these patients would create bias.
The mean age of the 172 patients who were included in the study was 39 years (14-78). The study group comprised 110 (64%) males, and 62 (36%) females. Using all-cause admissions to the medical wards during the study period, it was found that males were at greater risk of developing empyema (p-value < 0.0001; OR 2.40; 95% CI 2.00-2.88).
HIV infection was present in 125 (73%) patients (see Figure 2 ).
With regard to the reported risk factors for the development of empyema, statistical differences were found among the HIVinfected and non-infected groups for age (p-value = 0.0003) and sex (p-value = 0.05). In HIV-infected patients stratified according to CD4 cell count, ethanol abuse was found to be significant (p-value = 0.04). No differences in risk factors were found in HIV-infected patients stratified according to ARV usage.
Microbiological aetiologies were as follows: 34 (19.8%) patients had proven tuberculosis; 34 (19.8%) had clinical tuberculosis; 8 (4.7%) had dual infections; 55 (32%) had bacterial infections; 1 (0.6%) had non-tuberculosis mycobacterial infection, and in 40 (23.3%), no microbiological aetiology was identified. One patient cultured both Streptococcus pneumoniae and nontuberculosis mycobacteria, and was classified as "bacterial". We report five cases of Salmonella non-typhi empyema, all of which were HIV infected. Four had CD4 counts < 100 cells/mm 3 and the fifth was on ARV therapy and had a CD4 count of 118 cells/mm 3 . Pleural fluid cultured Salmonella spp. in all five. In one, Salmonella spp. was also cultured on sputum (Table I) .
With regard to the aetiology, usually HIV-non-infected patients had no identifiable microbiological aetiology (p-value < 0.005; OR 0.18; CI 0.08-40), whereas HIV-infected patients with lower CD4 cell counts had a significantly greater likelihood of being diagnosed with clinical tuberculosis (p-value = 0.02; OR 2.98; CI 1.22-7.3), and showed a trend towards having a greater incidence of infections caused by Gram-negative organisms (OR 10.6). ARV therapy did not alter the aetiology of empyema.
Tube thoracostomas were inserted in the general medical wards in all but 11 (6.4%) patients. Six (3.5%) were transferred to cardiothoracic surgeons, as their pleural collections were not amenable to tube thoracostomy. Three (1.8%) had very small collections which were treated medically, and 2 (1.2%) refused further hospital treatment.
Following closed-tube thoracostomy, 16 (10%) patients had complete resolution of empyema within 14 days, and 34 (20.4%) had resolution with prolonged drainage or multiple tubes. Following 14 days of closed-tube thoracostomy, 47 (28.1%) were discharged home with an open-tube thoracostoma, 14 (29.8%) of these following basal tube insertion by cardiothoracic surgeons. Thirty-eight (22.8%) patients underwent cardiothoracic surgery. Thirty-five had pleural toilette and basal tube insertion with subsequent resolution, one had a decortication, and two required thoracostomy. Prior to resolution of empyema, a further 12 (7%) patients refused further treatment, and discharged themselves from hospital. follow-up, 5 (10.6%) were transferred to cardiothoracic surgeons for a definitive procedure (toilette, decortication, thoracostomy or thoracoplasty), and 2 (4.3%) demised due to ongoing pleural sepsis.
The overall length of stay was a median of 29 days (3-118 days). No differences were found with regard to length of stay between HIV-infected and non-infected patients, or between those stratified according to CD4 cell count. Patients on ARV therapy had significantly shorter lengths of stay.
Patients were evaluated for development of complications. Four (2.4%) developed wound sepsis at the tube thoracostomy site, and 26 (15.6%) developed secondary infection of their pleural space. Mortality in this series was 12.8% (22/172), 20 patients died in the medical wards and two died post surgical intervention.
Regarding outcomes and complications, HIV-infected patients on ARVs are more likely to be offered definitive cardiothoracic intervention. Length of stay was shorter, and though not statistically significant, there were no mortalities amongst patients on ARV therapy. No other differences were found between the various groups (see Table II ).
Discussion
Empyema thoracis remains an important problem in South Africa. The majority of empyemas (> 50%) are as a result of direct extension of a pulmonary parenchymal infection into the pleural space. 1,3 Empyema in HIV-infected patients is uncommon in developed countries, despite the increased risk that HIV infection confers to the development of respiratory infections. 8, 9 In this series, at an ecological level, there appears to be a strong association between HIV infection and the 3 Since the availability of antibiotics, the bacteriology has changed. S. pneumoniae and S. pyogenes infections occur less frequently, and S. aureus and enteric Gram-negative organisms occur more frequently. 10, 11 Infections caused by Gram-negative organisms occur more often in HIV-infected patients, 8 and this trend was found in our series. Infection with non-typhoidal Salmonella is well described in patients with advanced HIV infection. 12 Bacteraemia occurs frequently. However, pleuropulmonary complications are rare, with empyema usually occurring in the setting of CD4 counts < 100 cells/mm. 3, 13, 14 The incidence of non-typhoidal Salmonella reported in our series suggests that it should be considered a potential aetiological organism in HIV-infected patients with low CD4 cell counts. The identification of Pseudomonas aeruginosa and Acinetobacter baumannii as causes of empyema is worrying, and may reflect the increased contact that HIV-infected patients have with health facilities. There appears to be a resurgence of important pathogens from the pre-antibiotic era in the presence of the HIV pandemic.
Tuberculosis empyema has been reported at frequencies of 3-6% in developed countries. 7, 8, 15 However, in developing countries, tuberculosis accounts for up to 35% of cases. 4 In southern Africa, the majority of patients with tuberculosis empyema are HIV infected. 16 Rates of tuberculosis empyema were higher in our series than those stated in developed countries. When combining the patients with proven and clinical tuberculosis, 44.2% of empyemas are attributed to tuberculosis infection. HIV-infected patients tend to be given the diagnosis of clinical tuberculosis when no microbiological aetiology is found, despite extensive investigation. We attribute this to clinician bias in a community where rates of HIV and tuberculosis co-infection are high. Dual infections were only found in patients with HIV infection, and occurred over a range of CD4 counts (39-382 cells/mm 3 ).
Pleural involvement is unusual with non-tuberculosis mycobacteria. Pleural thickening, adjacent to pulmonary parenchymal infection, is described, and pleural effusions, if present, are very small. 17, 18 Empyema is rare, with only one report of a clearly documented empyema, due to nontuberculosis mycobacteria, in a patient with advanced acquired immunodeficiency syndrome. 19 Non-tuberculosis mycobacteria were cultured in two patients (M. aviumintracellulare in one, and failed identification of species in the other, due to contamination). Both patients were HIV infected, with advanced disease. The CD4 counts were 7 and 25 cells/ mm 3 . Neither was on ARV therapy.
Despite thorough investigation, no identifiable microbiological aetiology for empyema was identified in 23.3% of patients. Patients may have been treated with antibiotics prior to admission, or specimens for anaerobic cultures may not have been optimally processed, thus anaerobic infections were underreported. Anaerobic bacteria remain important pathogens in adults. 20 Rapid transfer in oxygen-free media to the laboratory and adequate anaerobic culture techniques are vital to increase diagnostic sensitivity. 10 The treatment of empyema depends upon the pathophysiological stage in which the patient presents. Empyemas in the exudative stage may be successfully drained via closedtube thoracostomy. 7, 21, 22 Empyemas in the fibrinopurulent stage often require more aggressive drainage procedures or video-assisted thoracoscopy. [21] [22] [23] There is contradictory evidence on the use of intrapleural fibrinolytics. They may be used as an adjunct to closed tube thoracostomy. However, they do not reduce mortality or the need for surgery. 24, 25 Thoracoscopic drainage procedures are popular, with less postoperative pain, lower costs, shorter hospital stays, and better cosmetic results. 24, 26 Optimal timing is important as high failure rates have been reported in cases with advanced empyema. 27, 28 Empyema, in the organisational stage, is best managed via open surgery; decortication, thoracostomy or thoracoplasty, to manage extensive pleural peel, or control the underlying inflammatory process. 7, 21, 23 Decortication remains the modality of choice for treating advanced empyema. Thoracoplasty and thoracostoma are reserved for debilitated patients who cannot tolerate aggressive surgery, or those in whom decortication has failed. 21, 29 The success rate of closedtube thoracostomy for advanced or loculated empyema is low, 7, 21 while the mortality of empyema treated by closed-tube thoracostomy is high (11-24%). 21, 29 In our series, 30.4% of patients were successfully treated via closed-tube thoracostomy. However, many required multiple tubes or prolonged drainage. Cardiothoracic intervention, as a primary therapeutic measure, was offered to only 6 (3.5%) patients, and surgery was offered to another 46 (26.7%). Development of local complications in 15 (28.9%) patients, or the necessity for multiple tube insertions in 15 (28.9%), appeared to be the criteria for surgery. Surgery was more readily offered to patients on ARV therapy.
Long-term open-tube thoracostomy via a tube thoracostomy cut short, and the placement of a colostomy bag over the cut end of the tube, is a technique (which we could not find described in the literature) that we used, due to the limited cardiothoracic resources available to us. The empyema space is allowed to drain freely, and with regular withdrawal of the tube, the pleural space eventually obliterates. Of the 47 patients discharged with open-tube thoracostomas, we were able to assess the outcomes in 38%. Of these, 11 (61%) patients had ultimate resolution. Thus, opentube thoracostomy may be a viable alternate treatment option in settings with limited cardiothoracic services. The high rate of patients lost to follow-up does not allow for accurate assessment. However, it is an intriguing alternative treatment, and further prospective studies should be undertaken to assess this method further. A significant proportion of patients refused hospital treatment. They had either required multiple-tube insertion, or waited for long periods of time for cardiothoracic intervention. Mortality in this series is in line with that reported in current literature, but it may be underreported, considering that many patients refused hospital treatment or were lost to follow-up.
Although this is a very large retrospective case series of empyema in HIV-infected patients, this study is limited by the sample size of the sub-groups, and may not have had sufficient power to demonstrate statistical significance between the various groups. The fact that cardiothoracic surgery was offered largely only to patients on ARV therapy is a further limitation, as we were only able to assess whether patients underwent surgery as opposed to the need, as described in the literature, for cardiothoracic intervention. Only subjects referred to the respiratory unit were analysed, and subjects with uncomplicated courses may have been excluded.
Conclusion
This is the largest series to be published in the literature of empyema in HIV-infected patients. It suggests that HIV infection is strongly associated with the development of empyema. We were unable to show that HIV alters the aetiology of empyema. However, a trend towards infection with enteric Gram-negative organisms, in particular Salmonella spp., was found and a further case of non-tuberculosis mycobacteria empyema is described. Clinical outcomes were similar in HIV-infected and HIV-non-infected patients. With regard to surgical intervention, bias towards patients on ARV therapy exists, and may translate into shorter length of stay or even reduced mortality.
